ABUS Arbutus Biopharma Corporation

+0  (2%)
Previous Close 3.30
Open 3.30
Price To book 0.89
Market Cap 184.33M
Shares 55,023,000
Volume 222,764
Short Ratio 8.76
Av. Daily Volume 188,277

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 Cohort 4 data due 4Q 2017.
Hepatitis B (HBV)
Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
Hepatocellular carcinoma (HCC)

Latest News

  1. Arbutus Announces ARB-1467 Data Presentation at EASL
  2. Arbutus Injunction Survives Attempted Appeal by Acuitas
  3. Arbutus Announces Appointment of Daniel Burgess to Board of Directors
  4. Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: 2016 By the Numbers : March 23, 2017
  5. Edited Transcript of ABUS earnings conference call or presentation 21-Mar-17 6:00pm GMT
  6. Arbutus Announces Year-End 2016 Financial Results
  7. Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
  8. Alexion Buys LNP Drug Delivery Tech from Arbutus
  9. Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate
  10. Arbutus to Participate in Upcoming Investor Conferences
  11. SBPH: 2016 Results Sustaining Continued HBV/STING Development
  12. Doylestown biopharm firm granted injunction over licensing dispute
  13. Mysterious $5 Billion Biotech Moderna Hit With Legal Setback Related To Key Technology
  14. Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology
  15. Celgene Issues Preliminary 2016 Results, Lifts 2017 View
  16. Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
  17. Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
  18. The Medicines Co LDL-Lowering Drug Positive in Phase II
  19. Ultragenyx's (RARE) KRN23 Accepted for Review in the EU